Saturday, September 26, 2020
8:00 AM – 2:45 PM (ET)

 

 

Program Overview

The 2020 Hospital Medicine Summit (HMS) is an innovative, multi-supported, multifaceted educational initiative designed for hospital-based and internal medicine clinicians, including physicians, physician assistants, nurse practitioners, pharmacists, and nurses. The program aims to provide important educational updates from leading experts on conditions that are commonly encountered by healthcare clinicians practicing in the hospital and internal medicine settings.

HMS Live Webcast

In response to the ongoing coronavirus pandemic and to ensure safe and effective transfer of these important educational updates, Integrity Continuing Education invites you to attend a live web broadcast of the 2020 Hospital Medicine Summit. This engaging, interactive live webcast will provide participants the ability to ask questions and participate in all polling exercises in real time, thus simulating the experience of a live, in-person program.

Faculty

Alpesh Amin, MD, MBA, FACC, MACP, SFHM
Thomas & Mary Cesario Chair of Medicine
Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering
Executive Director, Hospitalist Program
Medical Director, Anticoagulation Services
University of California, Irvine
Irvine, California

Jasmohan S. Bajaj, MD, AGAF, FAASLD
Professor of Medicine
Divisions of Internal Medicine, Gastroenterology,
Hepatology, and Nutrition
Virginia Commonwealth University and
McGuire VA Medical Center
Richmond, Virginia

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair
in Preventive Cardiology
Professor of Medicine
John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, Louisiana

William Fischer II, MD
Associate Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Bruce S. Spinowitz, MD
Associate Director, Nephrology
Vice Chairman, Medicine
New York Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York

Program Agenda

All times stated are in Eastern Time.

^*Agenda subject to change

Target Audience

This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital and internal medicine settings.

Learning Objectives

Session 1 Keynote – The Impact of COVID-19 on Hospital Medicine

• Discuss the impact of COVID-19 on hospital-based practice in the US
• Describe lessons learned in hospital surge and emergency medical preparedness
• Review and highlight key successes in the US healthcare system response to COVID-19

Session 2 – Optimizing Transitions from Hospital to Home: Best Practices for Reducing Readmissions in Heart Failure

• Apply diagnostic and assessment criteria to the effective management of patients with heart failure (HF)
• Integrate current guideline-directed medical therapy (GDMT) and recent clinical trial outcomes into the effective management of patients with HF
• Develop a comprehensive GDMT approach to HF management in patients who have recently experienced an acute heart failure episode
• Review proven strategies to achieve successful transitions of care in patients with HF

Session 3 – Assessment and Management of Hyperkalemia in the Hospital Setting: Optimizing Patient Outcomes

• Identify factors that increase risk for hyperkalemia
• Discuss the relationship between RAAS inhibitors and hyperkalemia development in patients with chronic kidney disease, heart failure, hypertension, and/or diabetes mellitus
• Apply to practice an understanding of clinical trial evidence for the efficacy and safety of newer potassium binders approved for treating hyperkalemia
• Employ a multidisciplinary, team-based approach to improve outcomes for patients with hyperkalemia

Session 4 – Drift, Shift, Evolve: Keeping Abreast of the Role of Antiviral Therapy in the Management of Seasonal Influenza

• Appraise the role of vaccination in reducing the spread of influenza and improving patient outcomes
• Employ updated guidelines for the diagnosis of influenza in the hospitalized patient
• Determine appropriate use of antiviral chemoprophylaxis for individuals at risk of influenza and associated complications
• Compare current and emerging antiviral agents based on efficacy and safety, dosage and administration, and reduction in duration of illness and complications in order to make individualized treatment decisions for patients with influenza

Session 5 – Hepatic Encephalopathy: Achieving Care Goals in the Acute Setting and Beyond

• Describe an approach to the early diagnosis of hepatic encephalopathy (HE) that is consistent with current guideline recommendations
• Summarize clinical trial data on the efficacy and safety of options for acute treatment and prophylaxis of HE
• Implement a transitional care plan to prevent future hospitalizations of patients with HE

Accreditation

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this free live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this free continuing education activity for 6.0 contact hours (0.60 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Numbers – 0530-9999-20-070-L01-P, 0530-9999-20-071-L01-P, 0530-9999-20-072-L01-P, 0530-9999-20-073-L01-P, 0530-9999-20-074-L01-P.)

This is a knowledge-based activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This free educational activity for 6.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete each session’s pretest and posttest, attend/participate in each session, and complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity. ACPE credit will not be issued after 60 days.

Fee Information

There is no fee for this online live educational activity.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

System Requirements

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

 

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Rachel Brown, PharmD, MPH, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, Ashley Marostica, RN, MSN, Michelle R. Rizzo, ELS, Patima Tanapat, PhD.

Faculty Disclosures

Alpesh Amin, MD, MBA, FACC, MACP, SFHM
Dr. Amin does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity.

Jasmohan S. Bajaj, MD, AGAF, FAASLD
Consulting Fees: Kaleido Biosciences; Contracted Research: Cosmo Pharmaceuticals,
Grifols, S.A., Valeant Pharmaceuticals.

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Consultant: Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Quantum Genomics, Sanofi.

William A Fischer II, MD
Serves on Adjudication Committees for Janssen Pharmaceutica and Syneos Health.

Bruce S. Spinowitz, MD
Consulting Fees: Akebia Therapeutics, AstraZeneca, Reata Pharmaceuticals.
Contracted Research: Akebia Therapeutics, AstraZeneca, Bayer, Gilead, GlaxoSmithKline, Reata Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Provider Statement

       

This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

Supporter Acknowledgement

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Genentech, a member of the Roche Group; Novartis Pharmaceuticals Corporation; and Salix Pharmaceuticals, Inc.